BRIEF-GSK says gene therapy for immune disorder meets main goal By: Reuters: Company News May 25, 2016 at 05:09 AM EDT * Key efficacy endpoint for analysis was survival. All 18 patients were alive after a median follow-up of 6.9 years at data cut on 8th may 2014 Read More >> Related Stocks: Gsk Plc ADR